Reasons to remain bullish. Not guaranteed, slower than we like, and not clear, but pathways surely exist.
The more likely near-term scenario is: Canadian companies buying or partnering with U.S. operators, licensing brands/IP, pharmaceutical/medical cannabis channels.
Tilray is already preparing through beverages, hemp products, and strategic positioning. Why Canada still matters. Canadian companies actually have advantages: federally legal operating experience, pharmaceutical-grade production, international export expertise, existing public-market infrastructure. Plus Tilray is a diversified CPG company with beverages and health food.
Personally, I believe it will be a partnership with a U.S. company and medical channels. The rest probably likely over time.
Stock price is a separate issue and will benefit due to clearer pathways and rise with the U.S. cannabis sector.
Industry moving forward.